Adam Veness Sells 30,000 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) SVP Adam Veness sold 30,000 shares of Dianthus Therapeutics stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the transaction, the senior vice president directly owned 30,000 shares of the company’s stock, valued at approximately $2,424,000. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Dianthus Therapeutics Stock Performance

Shares of DNTH opened at $82.49 on Friday. Dianthus Therapeutics, Inc. has a fifty-two week low of $16.64 and a fifty-two week high of $96.50. The firm’s 50-day simple moving average is $86.64 and its two-hundred day simple moving average is $66.39. The stock has a market cap of $4.51 billion, a PE ratio of -19.97 and a beta of 1.18.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.22. The firm had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. Equities research analysts predict that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of hedge funds have recently added to or reduced their stakes in DNTH. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Dianthus Therapeutics by 4.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after acquiring an additional 618 shares in the last quarter. American Century Companies Inc. increased its holdings in shares of Dianthus Therapeutics by 13.2% in the 2nd quarter. American Century Companies Inc. now owns 54,140 shares of the company’s stock worth $1,009,000 after purchasing an additional 6,323 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Dianthus Therapeutics by 31.1% in the 2nd quarter. Invesco Ltd. now owns 20,940 shares of the company’s stock worth $390,000 after purchasing an additional 4,962 shares in the last quarter. Alliancebernstein L.P. increased its holdings in shares of Dianthus Therapeutics by 14.5% in the 2nd quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company’s stock worth $21,887,000 after purchasing an additional 149,200 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of Dianthus Therapeutics in the second quarter worth $27,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have commented on DNTH shares. Stifel Nicolaus set a $120.00 target price on Dianthus Therapeutics in a report on Monday, March 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Monday, April 20th. Raymond James Financial restated a “strong-buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Wolfe Research reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Wall Street Zen raised shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $117.82.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.